CARsgen Therapeutics Holdings Limited (02171) released a Next Day Disclosure Return dated 21 November 2025, disclosing changes in its issued shares and treasury shares under repurchase arrangements.

According to the document, the company had an opening balance on 20 November 2025 of 574,806,905 issued shares (excluding treasury shares) and 3,135,500 treasury shares, totaling 577,942,405 shares. On 21 November 2025, 235,000 shares were repurchased at a volume-weighted average price of HKD 16.9484 and held as treasury shares, resulting in a closing balance of 574,571,905 issued shares (excluding treasury shares) and 3,370,500 treasury shares.

Additionally, the announcement reported shares repurchased for cancellation but not yet canceled: 250,000 shares on 21 October 2025 at HKD 17.08 and 205,000 shares on 23 October 2025 at HKD 16.58.

A separate repurchase report showed that on 21 November 2025, 235,000 ordinary shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 16.57 to HKD 17.09 per share, totaling HKD 3,982,874. None of these were canceled and are being held as treasury shares.

The repurchase mandate was granted on 22 May 2025, authorizing up to 57,543,590 shares for potential repurchase. As of this announcement, 3,825,500 shares have been repurchased under this mandate. The moratorium period for any new share issues or transfers of treasury shares following the latest repurchase extends until 21 December 2025.